文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial.

作者信息

Brum Wagner S, Docherty Kieran F, Ashton Nicholas J, Zetterberg Henrik, Hansson Oskar, McMurray John J V, Blennow Kaj

机构信息

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

出版信息

JAMA Neurol. 2024 Feb 1;81(2):197-200. doi: 10.1001/jamaneurol.2023.4719.

DOI:10.1001/jamaneurol.2023.4719
PMID:38109077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10728797/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a1/10728797/ca8ea601911d/jamaneurol-e234719-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a1/10728797/b3d676d5b04c/jamaneurol-e234719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a1/10728797/ca8ea601911d/jamaneurol-e234719-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a1/10728797/b3d676d5b04c/jamaneurol-e234719-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17a1/10728797/ca8ea601911d/jamaneurol-e234719-g002.jpg

相似文献

[1]
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Neurol. 2024-2-1

[2]
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Cochrane Database Syst Rev. 2018-6-28

[3]
Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.

Eur Heart J. 2025-1-28

[4]
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF.

JACC Heart Fail. 2025-6

[5]
Use of Angiotensin Receptor Neprilysin Inhibitor in Patients on Maintenance Hemodialysis with Reduced Cardiac Ejection Fraction, Real-World Experience From a Single Center.

Iran J Kidney Dis. 2021-7

[6]
Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis.

Future Cardiol. 2025-6

[7]
Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.

JAMA Netw Open. 2022-9-1

[8]
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.

Circ Heart Fail. 2018-10

[9]
Effect of angiotensin receptor neprilysin inhibitor on physical activity in patients with heart failure with reduced ejection fraction, monitored by implantable electronic device home monitoring.

J Cardiovasc Med (Hagerstown). 2024-3-1

[10]
Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials.

Am J Cardiol. 2023-10-15

引用本文的文献

[1]
Assessment of Cognitive Function via Biomarkers in Japanese Patients With Chronic Heart Failure Treated With Angiotensin-Receptor-Neprilysin Inhibitor.

Circ Rep. 2025-5-24

[2]
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis.

EBioMedicine. 2025-6-12

[3]
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer's disease.

EBioMedicine. 2025-6

[4]
Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.

Alzheimers Dement. 2025-5

[5]
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study.

Eur Heart J Cardiovasc Pharmacother. 2025-8-12

[6]
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders.

Nat Rev Drug Discov. 2025-4-4

[7]
Proceedings of the Alzheimer's Diagnosis in Older Adults With Chronic Conditions Network Inaugural Annual Conference.

J Gerontol A Biol Sci Med Sci. 2025-5-5

[8]
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

Alzheimers Dement. 2025-3

[9]
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.

Alzheimers Res Ther. 2025-2-19

[10]
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.

Pharmaceuticals (Basel). 2024-12-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索